Archive · 19 Sep 2026
FSSAI Files Three Cases Against Nestlé India Infant Products
India’s food regulator examined three Nestlé infant nutrition products and their online promotional material.
It questioned claims about “5 HMOs” and whey protein on NAN Excella Pro Stage 1.
It also questioned a claim that Lactogen Pro 1’s whey protein was easy to digest.
Separately, a follow-up formula sample did not meet the required biotin level.
Another laboratory tested the sample and found the same problem.
FSSAI then filed three legal cases against Nestlé India.
Nestlé said its products and labels follow all applicable rules.
The company also said its claims were factual and supported by scientific research.
The cases are still proceedings, so they do not yet represent a final finding or penalty.
FSSAI filed three separate adjudication cases against Nestlé India over three infant nutrition products.
The regulator flagged “5 HMOs” and “Whey Protein” claims on NAN Excella Pro Stage 1.
It questioned Lactogen Pro 1’s claim that its whey protein was “easy to digest.”
A follow-up formula sample failed prescribed biotin requirements in both initial and referral laboratory tests.
Nestlé India said its products and labels comply with regulations and are supported by scientific literature.
- Who
- The Food Safety and Standards Authority of India (FSSAI) and Nestlé India Limited.
- What
- FSSAI initiated three adjudication cases concerning promotional claims on two products and biotin non-compliance in a follow-up formula sample.
- When
- Friday, September 18, 2026.
- Where
- FSSAI examined products and promotional material available on e-commerce platforms in India; the market reaction was reported on Indian stock exchanges.
- Why
- FSSAI said promotional claims on two products violated infant-food advertising restrictions and that a follow-up formula sample failed prescribed biotin requirements.
FSSAI’s Findings
Nestlé India’s Response
Promotional claims
FSSAI’s Findings
FSSAI said claims involving “5 HMOs,” “Whey Protein,” and whey protein being easy to digest contravened restrictions on promotional claims and advertising for infant foods.
Nestlé India’s Response
Nestlé India said the statements were factual, supported by scientific literature, and that the NAN Excella Pro and Lactogen Pro labels had been approved by an FSSAI expert committee.
Product compliance
FSSAI’s Findings
FSSAI said a follow-up formula sample was below the prescribed biotin requirement in both initial and referral laboratory analyses.
Nestlé India’s Response
Nestlé said its products were fully compliant with applicable regulations and that it had submitted a detailed response to the authorities.
Status of the cases
FSSAI’s Findings
FSSAI filed three adjudication cases as part of its enforcement action against the alleged violations.
Nestlé India’s Response
Nestlé disputes the regulator’s interpretation of the claims; the articles do not report a final adjudication outcome or penalty.
- Regulator
- Food Safety and Standards Authority of India (FSSAI)
- Company
- Nestlé India Limited
- Products
- NAN Excella Pro Stage 1, Lactogen Pro 1, and a separate follow-up formula
- Claims flagged
- “5 HMOs” and “Whey Protein” for NAN Excella Pro Stage 1; whey protein described as easy to digest for Lactogen Pro 1
- Regulations cited
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, and Section 3 of the Infant Milk Substitutes Act, 1992
- Laboratory finding
- The follow-up formula failed prescribed biotin requirements in both initial and referral laboratory analyses
- Biotin standard
- The cited standard requires 7.5–50 micrograms per 100 grams, or 1.6–10.6 micrograms per 100 kcal
- Market reaction
- Reports described intraday declines of roughly 2% to 3%; one report said shares closed 1.38% lower at ₹1,353.10 on the BSE
Sources
Nestle India share price falls 3%: FSSAI takes legal action over 3 baby products
FSSAI moves against Nestlé over baby formula claims and biotin test
‘Adherence to regulations’: Nestle India responds to FSSAI action over infant food products – NAN Excella, Lactogen Pro
After Maggi in the soup, has Nestlé missed the formula for baby food in India?
FSSAI Flags Nestlé Infant Products Over Biotin Levels: What Parents Should Know Before Buying
FSSAI Files Cases Against Nestle India Over Infant Nutrition Products; Shares Fall 2%
FSSAI files 3 adjudication cases against Nestlé India over infant formula non-compliance
FSSAI Action Against Nestle India: Infant Nutrition Products Under Scanner; Shares Fall 2%
FSSAI initiates legal action against Nestle India over non-compliant baby food products
FSSAI initiates legal action against Nestle India over three infant nutrition products, shares fall 2%
Food Authority Files 3 Cases Against Nestle India Over Infant Formula Products
FSSAI moves against Nestle over infant products
FSSAI Initiates Legal Action Against Nestle India Over Infant Nutrition Products
